Ascendis Pharma AS (ASND) — Technical state
As of 2026-11-02 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.
The Closelooknet read
- Closelooknet score: 53 out of 100 (momentum 65 · quality 63 · valuation 25), as of 2026-11-03.
- Signal: Uptrend stack intact — Trades +2.8% vs the 50-day and +4.5% vs the 200-day average, 11.8% below the 52-week high and +32.4% off the 52-week low. Computed from daily closes. (as of 2026-11-02)
- Trend: Ascendis Pharma AS trades 2.8% above its 50-day and 4.5% above its 200-day moving average. (as of 2026-11-02)
Ascendis Pharma builds drugs on its TransCon platform, which controls how a molecule releases in the body over time. It sells Skytrofa for children with growth hormone deficiency and Yorvipath for adults with chronic hypoparathyroidism.
The full read — the desk's view, the earnings record, peers and the company snapshot — is on the ASND overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.
Trades +2.8% vs the 50-day and +4.5% vs the 200-day average, 11.8% below the 52-week high and +32.4% off the 52-week low. Computed from daily closes.
The moving-average stack
- vs 20-day+5.5%
- vs 50-day+2.8%
- vs 200-day+4.5%
- 52-week band11.8% off the high · +32.4% off the low
- Streak2 consecutive down sessions
- 50-day crossprice crossed up through the 50-day 7 sessions ago
- Stochastic%K 80.3 · %D 94.1
Continue: the ASND chart & overview · quality & forensics · the earnings record · the signal board
FAQ · from the current data · as of 2026-11-02
Quick answers
What is the current Closelooknet signal on ASND?
Uptrend stack intact — Trades +2.8% vs the 50-day and +4.5% vs the 200-day average, 11.8% below the 52-week high and +32.4% off the 52-week low. Computed from daily closes. As of 2026-11-02; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.
Is ASND above its 50-day and 200-day moving averages?
As of 2026-11-02, Ascendis Pharma AS trades +2.8% above its 50-day and +4.5% above its 200-day average, with the 20-day +5.5% away.
How far is ASND from its 52-week high?
11.8% below the 52-week high and 32.4% above the 52-week low, as of 2026-11-02.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ARGX.BR Argen-Xindustry
- ONC BeiGene, Ltd.industry
- UCB.BR UCB SAindustry
- ARGX argenx NV ADRindustry
- REGN Regeneron Pharmaceuticals Incindustry
- KOD Kodiak Sciences Incindustry
- REPL Replimune Group Incindustry
- MRNA Moderna Incindustry
- EXEL Exelixis Incindustry
- ARQT Arcutis Biotherapeutics Incindustry
- VRDN Viridian Therapeutics Incindustry
- XNCR Xencor Incindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- BHVN Biohaven Ltd.industry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- KYMR Kymera Therapeutics Incindustry
- SEPN Septerna, Inc. Common Stockindustry
- ADMA ADMA Biologics Incindustry
- IRON Disc Medicine Inc.industry